NewCardio, Inc. NWCI

Company Overview

NewCardio, Inc. (OTC: NWCI) was a development-stage biotechnology company focused on cardiovascular disease diagnostics and drug discovery technologies. Based on historical public disclosures and SEC filings, the company operated within the life sciences and healthcare technology sectors, with an emphasis on improving cardiac safety assessment and identifying compounds with potential cardiovascular applications. Its primary activities centered on proprietary screening and analytical technologies designed to evaluate cardiac risk and electrophysiological effects during pharmaceutical development.

The company’s historical business model was tied to licensing, research collaborations, and the development of platform-based technologies rather than large-scale commercial product sales. Publicly available information indicates that NewCardio positioned itself around cardiac toxicity testing and predictive analytics for pharmaceutical developers. Historical records suggest the company evolved from an early-stage cardiovascular research enterprise into a smaller public biotechnology issuer with limited commercial scale. Data regarding more recent operational activity, active commercialization, or sustained revenue generation is inconclusive based on available public sources.